September 12, 2019 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 sseagraves@i2E.org Oklahoma-based Kirrhos Pharmaceuticals is developing a novel, first-in-class treatment for a severe form of non-alcoholic fatty liver disease known as NASH OKLAHOMA CITY — i2E, Inc., recently led an $850,000 seed investment in Oklahoma City-based Kirrhos Pharmaceuticals, which is developing a therapeuticRead more
i2E was created in response to an Oklahoma Center for the Advancement of Science and Technology (OCAST) initiative and has become
a nationally recognized private not-for-profit corporation.
Our mission is investing in entrepreneurs to build successful high growth companies in Oklahoma.
We achieve our mission by working directly with entrepreneurs, researchers and companies to help them commercialize their technologies,
launch and grow new businesses and access needed capital.
Our focus is on growing innovative small businesses in Oklahoma and making a positive impact on the state’s economy.